Category: Blog Posts

Genprex is once again leading the way in gene therapy and raising the standard in cancer treatment based upon its unique, proprietary technology platform that includes its non-viral vector nanoparticle delivery system.

Researchers at Johns Hopkins Medicine recently published a study in Science Advances that introduces a non-viral delivery system for gene editing. Genprex has already treated more than 50 patients in Phase I and II clinical trials using its proprietary non-viral delivery system.

Cancer is a complex disease that can be difficult treat. Lung cancer specifically is the leading cause of cancer deaths worldwide, causing more deaths than breast, colon, kidney, liver or prostate cancers.

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is researching and developing therapies for the treatment of lung cancer….

Genprex recently announced that independent researchers found that company’s TUSC2 (tumor suppressor candidate 2) prevented tumor growth in triple-negative breast cancer (TNBC). These independent researchers have no affiliation with Genprex.

Genprex takes a deeper dive into the data of the study to provide analysis and a better understanding of what the study found and what it means for TUSC2….

Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients, is raising the standard in cancer treatment by developing what it calls an “immunogene therapy,” which harnesses the power of immunotherapy’s immunomodulation through the delivery of a gene therapy.

Gene therapies and immunotherapies are two different types of treatment….

Pfizer recently announced its plans to invest $500 million into its Sanford gene therapy manufacturing operations. This expansion would create 300 new jobs, and Pfizer’s biopharmaceuticals group president noted the company “passionately believes in gene therapy.”

This passion for gene therapy, which is seemingly shared with other large biopharma companies, is leading to substantial commitments of resources to gene therapy….

Today’s cancer treatment options are not one-size-fits-all. But Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based on a unique proprietary technology platform, is working on developing its initial drug candidate for NSCLC that would potentially benefit a large patient population who cannot currently benefit from approved therapies….

Earlier this month, Genprex’s President and Chief Operating Officer, Julien Pham attended the American Society of Gene & Cell Therapy’s 22ndAnnual Meeting in Washington, D.C., which brings together industry professionals committed to advancing knowledge, awareness and education of gene and cell therapy. This meeting serves as a catalyst to transform medicine by advancing gene and cell therapies to benefit patients and society….

Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies. So how exactly does gene therapy work? There are a couple of “traditional” approaches to this generally newer treatment option for rare diseases and cancer….

Thermo Fisher recently announced it is buying Brammer Bio, which provides viral vector manufacturing services for gene and cell therapy companies. This acquisition is one of the many we have seen recently, as several other large pharmaceutical companies have been acquiring emerging gene and cell therapy companies with promising drug pipelines or drug approvals, including Roche’s acquisition of Spark Therapeutics, Biogen’s buying of Nightstar Therapeutics and Pfizer’s purchase of Vivet Therapeutics….